Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye
Status:
Not yet recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
Diquafosol ophthalmic solution (DQS) stimulates P2Y2 receptors on the ocular surface, which
enhances mucin secretion from goblet cells. Therefore, tear film stability and hydration of
the ocular surface can be achieved independent from lacrimal glands function. While it has
been observed that 0.1 percent hyaluronate (HA) in artificial tears promotes corneal
re-epithelium and improves corneal healing.This prospective, open label pilot study will
include 60 eyes of 30 diabetic patients diagnosed with DED and will be randomly assigned to
either DQS (n=30 eyes) or ATD group (n=30 eyes). Participants in the DQS group will receive
3% Diquafosol ophthalmic solution, while HA group will receive 0.1% Sodium hyaluronate
artificial tears. The dosage for both drugs will be one drop, six times per day for 4 weeks.
Tear film lipid layer (TFLL), non-invasive breakup time (NITBUT), corneoconjunctival staining
score (CS), meibum gland (MG), conjunctival hyperemia (RS score), ocular surface disease
index (OSDI) will be assessed and compared at baseline, day-14, and day-28.